Abstract:Identification of proteins which initiate and/or perpetuate adaptive immune responses has potential to greatly impact pre-clinical and clinical work across numerous fields. To date, however, the methodologies available to identify antigens responsible for driving adaptive immune responses have been plagued by numerous issues which have drastically limited their widespread adoption. Therefore, in this study, we sought to optimize a shotgun immunoproteomics approach to alleviate these persistent issues and create a high-throughput, quantitative methodology for antigen identification. Three individual components of a previously published approach, namely the protein extraction, antigen elution, and LC-MS/MS analysis steps, were optimized in a systematic manner. These studies determined that preparation of protein extracts using a one-step tissue disruption method in immunoprecipitation (IP) buffer, eluting antigens from affinity chromatography columns with 1% trifluoroacetic acid (TFA), and TMT-labeling & multiplexing equal volumes of eluted samples for LC-MS/MS analysis, resulted in quantitative longitudinal antigen identification, with reduced variability between replicates and increased total number of antigens identified. This optimized pipeline provides a multiplexed, highly reproducible, and fully quantitative approach to antigen identification which is broadly applicable to determine the role of antigenic proteins in inciting (i.e., primary antigens) and perpetuating (i.e., secondary antigens) a wide range of diseases. SIGNIFICANCE: Using a systematic, hypothesis-driven approach, we identified potential improvements for three individual steps of a previously published approach for antigen-identification. Optimization of each step created a methodology which resolved many of the persistent issues associated with previous antigen identification approaches. The optimized high-throughput shotgun immunoproteomics approach described herein identifies more than five times as many unique antigens as the previously published method, greatly reduces protocol cost and mass spectrometry time per experiment, minimizes both inter- and intra-experimental variability, and ensures each experiment is fully quantitative. Ultimately, this optimized antigen identification approach has the potential to facilitate novel antigen identification studies, allowing evaluation of the adaptive immune response in a longitudinal manner and encourage innovations in a wide array of fields.

Enhancing Efficiency and Quality of Statistical Estimation of Immunogenicity Assay Cut Points Through Standardization and Automation.

Statistical Approaches for Establishing Appropriate Immunogenicity Assay Cut Points: Impact of Sample Distribution, Sample Size, and Outlier Removal

Challenging the Standard Immunogenicity Assessment Approach: 1-Tiered ADA Testing Strategy in Clinical Trials

Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points

Reformation of a Clinical Anti-Drug Antibody Assay to Enable the Immunogenicity Assessment of a Bispecific Antibody Biotherapeutic

A Step-wise Approach for Transfer of Immunogenicity Assays During Clinical Drug Development

Development of a Comprehensive Antibody Staining Database Using a Standardized Analytics Pipeline

Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays.

Standardization of flow cytometric detection of the antigen expression

Anti-drug Antibody Validation Testing and Reporting Harmonization

Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity

Identifying the critical cut-points of a quality control process for serological assays: results from parametric and semiparametric regression models

Assessment of A Method to Characterize Antibody Selectivity and Specificity for Use in Immunoprecipitation

Optimization of a high-throughput shotgun immunoproteomics pipeline for antigen identification

Neutralizing Antibody Validation Testing and Reporting Harmonization

Immunogenicity assessment strategy for a chemically modified therapeutic protein in clinical development

Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy

Characterization of Critical Reagents in Ligand-Binding Assays: Enabling Robust Bioanalytical Methods and Lifecycle Management

Anti-drug Antibody Assay Validation: Improved Reporting of the Assay Selectivity via Simpler Positive Control Recovery Data Analysis

Development and experimental validation of computational methods for human antibody affinity enhancement

Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework